ADALIMUMAB-AQVH

ADALIMUMAB-AQVH was reported 99 times

ADALIMUMAB-AQVH is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 SUBACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY 1 0.0294
1 ACNE FULMINANS 1 0.0051
2 FAILURE TO SUSPEND MEDICATION 1 0.0048
3 POLYCHONDRITIS 1 0.0024
4 DEVICE SAFETY FEATURE ISSUE 2 0.0020
5 RETINAL VASCULAR DISORDER 1 0.0017
6 SITTING DISABILITY 1 0.0016
7 GLOMERULONEPHRITIS MINIMAL LESION 1 0.0014
8 MALIGNANT ASCITES 1 0.0013
9 EOSINOPHILIC PNEUMONIA ACUTE 1 0.0012
10 GLOMERULONEPHRITIS RAPIDLY PROGRESSIVE 1 0.0009
11 ADENOCARCINOMA PANCREAS 1 0.0008
12 PRODUCT LEAKAGE 4 0.0007
13 CLEFT PALATE 1 0.0005
14 ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY POSITIVE VASCULITIS 1 0.0004
15 DEVICE MALFUNCTION 28 0.0004
16 ACCIDENTAL EXPOSURE TO PRODUCT 34 0.0003
17 PYODERMA GANGRENOSUM 1 0.0003
18 LIQUID PRODUCT PHYSICAL ISSUE 2 0.0003
19 DEVICE FAILURE 4 0.0003
20 DEVICE LEAKAGE 11 0.0003
21 POLYDIPSIA 1 0.0003
22 PRODUCT COMPLAINT 6 0.0002
23 ABSCESS LIMB 1 0.0002
24 DEVICE OPERATIONAL ISSUE 1 0.0002
25 INJECTION SITE PAPULE 1 0.0002
26 HYPERAMMONAEMIA 1 0.0002
27 DRUG DELIVERY SYSTEM MALFUNCTION 1 0.0002
28 PRODUCT TEMPERATURE EXCURSION ISSUE 1 0.0002
29 INJECTION SITE DISCHARGE 1 0.0002
30 DEVICE DEFECTIVE 3 0.0002
31 INJECTION SITE IRRITATION 2 0.0002
32 DEVICE DEPLOYMENT ISSUE 2 0.0002
33 CARDIAC FAILURE ACUTE 1 0.0001
34 INJURY ASSOCIATED WITH DEVICE 3 0.0001
35 DIFFUSE LARGE B-CELL LYMPHOMA 1 0.0001
36 PRODUCT DOSE OMISSION ISSUE 31 0.0001
37 NO ADVERSE EVENT 15 0.0001
38 INJECTION SITE URTICARIA 2 0.0001
39 DEVICE MECHANICAL ISSUE 1 0.0001
40 SKIN REACTION 1 0.0001
41 NEEDLE ISSUE 2 0.0001
42 PRODUCT QUALITY ISSUE 9 0.0001
43 BRAIN FOG 1 0.0001
44 MUSCULOSKELETAL DISCOMFORT 1 0.0001
45 DEVICE USE ERROR 2 0.0001
46 SYRINGE ISSUE 1 0.0001
47 PRODUCT ADMINISTERED AT INAPPROPRIATE SITE 1 0.0001
48 TUBULOINTERSTITIAL NEPHRITIS 1 0.0001
49 PRODUCT ADMINISTRATION ERROR 1 0.0000
50 PSORIATIC ARTHROPATHY 2 0.0000
51 DEVICE DIFFICULT TO USE 3 0.0000
52 DEVICE ISSUE 4 0.0000
53 HEART RATE IRREGULAR 1 0.0000
54 INCORRECT DOSE ADMINISTERED BY DEVICE 1 0.0000
55 DEVICE DELIVERY SYSTEM ISSUE 1 0.0000
56 INTENTIONAL DOSE OMISSION 1 0.0000
57 DRUG EFFECTIVE FOR UNAPPROVED INDICATION 1 0.0000
58 RASH MACULAR 1 0.0000
59 SYSTEMIC LUPUS ERYTHEMATOSUS 1 0.0000
60 THERAPY INTERRUPTED 2 0.0000
61 DYSARTHRIA 1 0.0000
62 DRUG DOSE OMISSION BY DEVICE 2 0.0000
63 INJECTION SITE BRUISING 2 0.0000
64 INJECTION SITE ERYTHEMA 3 0.0000
65 MENTAL DISORDER 1 0.0000
66 SKIN DISCOLOURATION 1 0.0000
67 HYPOKALAEMIA 1 0.0000
68 RASH PRURITIC 1 0.0000
69 HAEMATOCHEZIA 1 0.0000
70 INCORRECT DOSE ADMINISTERED 4 0.0000
71 SUICIDE ATTEMPT 1 0.0000
72 INJECTION SITE PRURITUS 1 0.0000
73 INJECTION SITE REACTION 1 0.0000
74 MOBILITY DECREASED 1 0.0000
75 HOT FLUSH 1 0.0000
76 UNEVALUABLE EVENT 1 0.0000
77 ACNE 1 0.0000
78 INJECTION SITE HAEMORRHAGE 1 0.0000
79 MYALGIA 2 0.0000
80 PRODUCT STORAGE ERROR 1 0.0000
81 MUSCULOSKELETAL STIFFNESS 1 0.0000
82 ADVERSE EVENT 1 0.0000
83 DYSPHAGIA 1 0.0000
84 CHEST DISCOMFORT 1 0.0000
85 ABDOMINAL PAIN UPPER 2 0.0000
86 ILLNESS 1 0.0000
87 HAEMORRHAGE 1 0.0000
88 MUSCULAR WEAKNESS 1 0.0000
89 RASH 3 0.0000
90 PAIN IN EXTREMITY 2 0.0000
91 CONDITION AGGRAVATED 2 0.0000
92 PAIN 4 0.0000
93 PARAESTHESIA 1 0.0000
94 PYREXIA 2 0.0000
95 MUSCLE SPASMS 1 0.0000
96 HYPERSENSITIVITY 1 0.0000
97 PRODUCT USE ISSUE 1 0.0000
98 ANAEMIA 1 0.0000
99 GAIT DISTURBANCE 1 0.0000
100 ARTHRALGIA 2 0.0000
101 PRODUCT USE IN UNAPPROVED INDICATION 1 0.0000
102 DRUG INEFFECTIVE 5 0.0000
103 WEIGHT DECREASED 1 0.0000
104 INJECTION SITE PAIN 1 0.0000
105 HEADACHE 2 0.0000
106 DIARRHOEA 2 0.0000
107 ASTHENIA 1 0.0000
108 PRURITUS 1 0.0000
109 FATIGUE 2 0.0000
110 OFF LABEL USE 2 0.0000
111 MALAISE 1 0.0000
112 NAUSEA 1 0.0000
113 DEATH 1 0.0000